Overall survival in patients with pancreatic cancer receiving matched therapies following molecular profiling: a retrospective analysis of the Know Your Tumor registry trialMichael J. Pishvaian, Emanuel F. Petricoin, Sara Bellakbira et al.|The Lancet Oncology|2020Cited by 541
Lymph-node-targeted, mKRAS-specific amphiphile vaccine in pancreatic and colorectal cancer: the phase 1 AMPLIFY-201 trialShubham Pant, Eileen M. O’Reilly, Zev A. Wainberg et al.|Nature Medicine|2024Cited by 234
Safety, Tolerability, and Preliminary Activity of LB-100, an Inhibitor of Protein Phosphatase 2A, in Patients with Relapsed Solid Tumors: An Open-Label, Dose Escalation, First-in-Human, Phase I TrialVincent Chung, John S. Kovach, Henry J. Durivage et al.|Clinical Cancer Research|2016Cited by 126
Abstract 1254: Preclinical studies with TGN-1062, a selective and reversible small molecule inhibitor of CDK7Ryan L. Rodriguez del Villar, Sunil Sharma, Trason Thode et al.|Cancer Research|2021Cited by 1
681 Clinical development of STL-101, a personalized TIL therapy for treatment of advance solid tumorsVincent Chung, Sunil Sharma, Raffaella Soldi et al.|Regular and Young Investigator Award Abstracts|2024Cited by 1